Imaging Diagnostic Systems Exhibits CT Laser Mammography At The Society Of Breast Imaging

Imaging
Diagnostic Systems, Inc., (OTC Bulletin Board: IMDS) a pioneer in laser
optical breast imaging systems, is exhibiting clinical cases from global
users of the CT Laser Mammography CTLM(R) system at the Society of Breast
Imaging (SBI) 8th Postgraduate Course, jointly sponsored by the American
College of Radiology, in Hollywood, Florida, April 14-17, 2007.


The course is intended for radiologists, radiologic technologists, and
medical physicists who are involved in breast imaging and interventional
procedures. Included among the objectives of the Course is the intent to
"assess new technologies for breast imaging and understand their potential
role and appropriate use in the evaluation of breast disease."



Deborah O'Brien, Imaging Diagnostic Systems' Senior Vice President
commented, "This is a wonderful opportunity to introduce CTLM technology to
breast imaging specialists, especially with our clinical results. The
proximity of the SBI Course to our facility also provides the opportunity
for researchers from our US PMA clinical sites to visit our headquarters."



About Imaging Diagnostic Systems, Inc.



Imaging Diagnostic Systems, Inc. has developed a revolutionary new
imaging device to aid in the detection and management of breast cancer. The
CTLM(R) system is a patented new breast imaging system that utilizes
continuous wave laser technology and patented algorithms to create 3-D
images of the breast. The procedure is non-invasive, painless, and does not
expose the patient to ionizing radiation or painful breast compression. CT
Laser Mammography (CTLM(R)) is designed to be used in conjunction with
mammography. It reveals information about blood distribution in the breast
and may visualize the process of angiogenesis, which usually accompanies
tumor growth.



Imaging Diagnostic Systems is currently collecting data from clinical
sites for the future filing of an FDA Premarket Approval (PMA) for the
Computed Tomography Laser Mammography (CTLM(R)) system to be used as an
adjunct to mammography. The FDA has determined that the Company's clinical
study is a non-significant risk (NSR) investigational device study under
812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR
812). The CTLM system is limited by United States Federal Law to
investigational use only in the United States. The CTLM system has received
other registrations including CE, CMDCAS Canadian License, China SFDA, UL,
ISO 9001:2000, ISO 13485:2003 and FDA export certification.



For more information, visit our corporate website: imds



As contemplated by the provisions of the Safe Harbor section of the
Private Securities Litigation Reform Act of 1995, this news release may
contain forward-looking statements pertaining to future, anticipated, or
projected plans, performances and developments, as well as other statements
relating to future operations. All such forward-looking statements are
necessarily only estimates or predictions of future results or events and
there can be no assurance that actual results or events will not materially
differ from expectations. Further information on potential factors that
could affect Imaging Diagnostic Systems, Inc., is included in the Company's
filings with the Securities and Exchange Commission. We expressly disclaim
any intent or obligation to update any forward-looking statements.


Imaging Diagnostic Systems, Inc.

imds